JHOP Articles

ASH Highlights, Myelodysplastic Syndromes

Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS

Original Research, Dose Escalation/Reduction, Multiple Myeloma, Chemotherapy, Adverse Events

Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan

Ekim Ekinci, PharmD, MS, BCOP, James E. Cox, PharmD, BCOP, Joe E. Ensor, PhD, Edward McLean, PharmD, BCOP, Carlos A. Ramos, MD, Premal D. Lulla, MD, Rammurti T. Kamble, MD, George Carrum, MD

Ekim Ekinci, PharmD, MS, BCOP; James E. Cox, PharmD, BCOP; Joe E. Ensor, PhD; Edward T. McLean, PharmD, BCOP; Carlos A. Ramos, MD; Premal D. Lulla, MD; Rammurti T. Kamble, MD; George Carrum, MD

Original Research, Chemotherapy, Infusion Issues, Adverse Events

Evaluation of Infusion-Related and Hypersensitivity Reactions to Chemotherapy Over a Decade at a Community Cancer Center

Sarah M. Hayes, PharmD, BCOP, Jeremy Whalen, PharmD, BCOP, Nick Schutz, PharmD, Joseph Levine, MD

Sarah Maryon Hayes, PharmD, BCOP; Jeremy Whalen, PharmD, BCOP; Nick Schutz, PharmD; Joseph Levine, MD

Original Research, Transplant, Adverse Events

Electrolyte Abnormalities and the Associated Risk for Atrial Fibrillation After Autologous Hematopoietic Stem-Cell Transplant

Natalie Schulze, PharmD, Kyle LaPorte, PharmD, Carol Breikreutz, PharmD, BCOP, Tobias Meissner, PhD, R. Vinod Parameswaran, MD, FRCPath, MRCP, Renju Raj, MD, Kelly McCaul, MD, ABIM, FRCPC

Natalie Schulze, PharmD; Kyle LaPorte, PharmD; Carol Breikreutz, PharmD, BCOP; Tobias Meissner, PhD; R. Vinod Parameswaran, MD, FRCPath, MRCP; Renju Raj, MD; Kelly McCaul, MD, ABIM, FRCPC

Cholangiocarcinoma

Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond

Cholangiocarcinoma

Combination of NUC-1031 plus Cisplatin Shows Promise as First-Line Treatment for Advanced Biliary Tract Cancer

Cholangiocarcinoma

FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance

Cholangiocarcinoma

Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must

Cholangiocarcinoma

Using Tumor Organoid-Based Functional Analysis to Predict Drug Sensitivities in Patients with Cholangiocarcinoma

Cholangiocarcinoma

Improving Chemotherapy Combinations and Novel Treatments Are Needed in Advanced Biliary Tract Cancer